CNTB
Get informed when a big investor buys or sells
+ FollowOvervalued by 69.7% based on the discounted cash flow analysis.
| Market cap | $156.78 Million |
|---|---|
| Enterprise Value | $119.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1 |
| Beta | -0.2 |
| Outstanding Shares | 55,660,000 |
| P/E Ratio | -4.95 |
|---|---|
| PEG | -5.93 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.58 |
| Enterprise Value to EBIT | -1.52 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4041▲ 40.41% |
|---|---|
| Total Calls | 196,500▲ 8.20% |
| Total Puts | 79,400▲ Infinity% |
Holdings and activity of institutional investors.
| Ownership % | 22.90%▲ 7.65% |
|---|---|
| Total Invested | $32.37M▲ 35.57% |
| Investors Holding | 46▲ 15.00% |
No data
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-d...